Do analysts rate ALDX or TXMD?

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 260.66%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend FBIO or TXMD?

Fortress Biotech presently has a consensus price target of $17.00, suggesting a potential upside of 535.28%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fortress Biotech is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TXMD or VRCA?

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 179.87%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Verrica Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate PYPD or TXMD?

PolyPid presently has a consensus price target of $11.33, suggesting a potential upside of 136.06%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYPD or TXMD more profitable?

TherapeuticsMD has a net margin of 5.34% compared to PolyPid's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -241.96% -126.91% TherapeuticsMD 5.34% 0.32% 0.23%

TherapeuticsMD (TXMD) Competitors

$2.09 +0.02 (+0.97%)

As of 12:26 PM Eastern

Compare

TXMD vs. ALDX, FBIO, VRCA, PYPD, and CGTX

Should you buy TherapeuticsMD stock or one of its competitors? MarketBeat compares TherapeuticsMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TherapeuticsMD include Aldeyra Therapeutics (ALDX), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), PolyPid (PYPD), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceuticals" industry.

How does TherapeuticsMD compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

TherapeuticsMD has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 260.66%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aldeyra Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Aldeyra Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
TherapeuticsMD	5.34%	0.32%	0.23%

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aldeyra Therapeutics had 3 more articles in the media than TherapeuticsMD. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 beat Aldeyra Therapeutics' score of -0.66 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Negative
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats Aldeyra Therapeutics on 8 of the 15 factors compared between the two stocks.

How does TherapeuticsMD compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

Fortress Biotech has higher revenue and earnings than TherapeuticsMD. Fortress Biotech is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.41	$6.82M	$3.17	0.84
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83

Fortress Biotech presently has a consensus price target of $17.00, suggesting a potential upside of 535.28%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts plainly believe Fortress Biotech is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Fortress Biotech had 4 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Fortress Biotech and 0 mentions for TherapeuticsMD. Fortress Biotech's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Fortress Biotech	Neutral
TherapeuticsMD	Neutral

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fortress Biotech has a net margin of 193.12% compared to TherapeuticsMD's net margin of 5.34%. Fortress Biotech's return on equity of 109.66% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
TherapeuticsMD	5.34%	0.32%	0.23%

Fortress Biotech has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Summary

Fortress Biotech beats TherapeuticsMD on 13 of the 15 factors compared between the two stocks.

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

TherapeuticsMD (NASDAQ:TXMD) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

TherapeuticsMD has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TherapeuticsMD has higher earnings, but lower revenue than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83
Verrica Pharmaceuticals	$35.58M	2.50	-$17.89M	-$1.67	N/A

TherapeuticsMD has a net margin of 5.34% compared to Verrica Pharmaceuticals' net margin of -102.84%. TherapeuticsMD's return on equity of 0.32% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Verrica Pharmaceuticals	-102.84%	-360.69%	-67.57%

Verrica Pharmaceuticals has a consensus target price of $14.50, suggesting a potential upside of 179.87%. Given Verrica Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Verrica Pharmaceuticals had 5 more articles in the media than TherapeuticsMD. MarketBeat recorded 5 mentions for Verrica Pharmaceuticals and 0 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.22 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Verrica Pharmaceuticals	Neutral

Summary

TherapeuticsMD and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does TherapeuticsMD compare to PolyPid?

PolyPid (NASDAQ:PYPD) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, PolyPid had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for PolyPid and 0 mentions for TherapeuticsMD. PolyPid's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
PolyPid	Neutral
TherapeuticsMD	Neutral

PolyPid has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

26.5% of PolyPid shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 24.7% of PolyPid shares are owned by insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83

TherapeuticsMD has a net margin of 5.34% compared to PolyPid's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
TherapeuticsMD	5.34%	0.32%	0.23%

PolyPid presently has a consensus price target of $11.33, suggesting a potential upside of 136.06%. Given PolyPid's stronger consensus rating and higher probable upside, equities research analysts plainly believe PolyPid is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats PolyPid on 8 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Cognition Therapeutics presently has a consensus price target of $3.33, suggesting a potential upside of 215.96%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
TherapeuticsMD	$3.02M	8.01	-$570K	$0.06	34.83

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

TherapeuticsMD has a net margin of 5.34% compared to Cognition Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-49.97%	-39.34%
TherapeuticsMD	5.34%	0.32%	0.23%

Cognition Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

In the previous week, Cognition Therapeutics had 4 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Cognition Therapeutics and 0 mentions for TherapeuticsMD. Cognition Therapeutics' average media sentiment score of 0.50 beat TherapeuticsMD's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
TherapeuticsMD	Neutral

Summary

Cognition Therapeutics beats TherapeuticsMD on 8 of the 15 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.18M	$11.91B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	34.83	788.49	269.93	24.86
Price / Sales	8.01	968.58	650.62	108.28
Price / Cash	44.37	15.12	28.89	37.44
Price / Book	0.90	10.34	11.25	6.44
Net Income	-$570K	$2.77B	$3.45B	$347.39M
7 Day Performance	2.45%	2.18%	3.67%	2.69%
1 Month Performance	4.50%	-1.35%	-0.49%	-0.90%
1 Year Performance	96.24%	191.22%	77.44%	23.51%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	1.1566 of 5 stars	$2.09 +1.0%	N/A	+94.4%	$24.18M	$3.02M	34.83	420	Upcoming Earnings
ALDX Aldeyra Therapeutics	3.1114 of 5 stars	$1.55 +1.3%	$5.50 +254.8%	-70.5%	$92.29M	N/A	N/A	10	Positive News Earnings Report
FBIO Fortress Biotech	2.0377 of 5 stars	$2.72 -1.4%	$17.00 +525.0%	+46.7%	$91.68M	$63.26M	0.86	170	Upcoming Earnings
VRCA Verrica Pharmaceuticals	2.0432 of 5 stars	$5.41 +3.0%	$14.50 +168.0%	-20.0%	$90.19M	$35.58M	N/A	40
PYPD PolyPid	2.4756 of 5 stars	$4.45 +2.1%	$11.33 +154.7%	+50.3%	$83.20M	N/A	N/A	80	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. ALDX, FBIO, VRCA, PYPD, and CGTX

How does TherapeuticsMD compare to Aldeyra Therapeutics?

Summary

How does TherapeuticsMD compare to Fortress Biotech?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Summary

How does TherapeuticsMD compare to PolyPid?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. ALDX, FBIO, VRCA, PYPD, and CGTX

How does TherapeuticsMD compare to Aldeyra Therapeutics?

Which has better earnings and valuation, ALDX or TXMD?

Do analysts rate ALDX or TXMD?

Which has more volatility & risk, ALDX or TXMD?

Is ALDX or TXMD more profitable?

Do institutionals and insiders have more ownership in ALDX or TXMD?

Does the media prefer ALDX or TXMD?

Summary

How does TherapeuticsMD compare to Fortress Biotech?

Which has better earnings & valuation, FBIO or TXMD?

Do analysts recommend FBIO or TXMD?

Does the media prefer FBIO or TXMD?

Do institutionals and insiders hold more shares of FBIO or TXMD?

Is FBIO or TXMD more profitable?

Which has more volatility and risk, FBIO or TXMD?

Summary

How does TherapeuticsMD compare to Verrica Pharmaceuticals?

Which has more volatility and risk, TXMD or VRCA?

Do institutionals & insiders hold more shares of TXMD or VRCA?

Which has better valuation and earnings, TXMD or VRCA?

Is TXMD or VRCA more profitable?

Do analysts prefer TXMD or VRCA?

Does the media refer more to TXMD or VRCA?

Summary

How does TherapeuticsMD compare to PolyPid?

Does the media prefer PYPD or TXMD?

Which has more risk and volatility, PYPD or TXMD?

Do insiders and institutionals hold more shares of PYPD or TXMD?

Which has preferable valuation & earnings, PYPD or TXMD?

Is PYPD or TXMD more profitable?

Do analysts rate PYPD or TXMD?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Do analysts prefer CGTX or TXMD?

Which has preferable valuation and earnings, CGTX or TXMD?

Do insiders & institutionals hold more shares of CGTX or TXMD?

Is CGTX or TXMD more profitable?

Which has more volatility & risk, CGTX or TXMD?

Does the media prefer CGTX or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools